Hydroxyurea

on 29.8.08 with 0 comments




  • mechanism of action: ribonucleotide reductase (RNR) inhibitor, so it’s S-phase specific and nonmutagenic

  • toxicity: myelosuppression

  • uses: myeloproliferative diseases (polycythemia vera, essential thrombocythemia); sickle-cell anemia

Category: Pharmacology Notes

POST COMMENT

0 comments:

Post a Comment